# A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

> **NCT04501276** · PHASE1 · COMPLETED · sponsor: **Adagene Inc** · enrollment: 72 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** ADG116
- **DRUG:** ADG106
- **DRUG:** anti PD1 drug

## Key facts

- **NCT ID:** NCT04501276
- **Lead sponsor:** Adagene Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2024-01-17
- **Final completion:** 2025-11-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501276, "A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04501276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*